Eli Lilly's retatrutide cut breathing interruptions and drove significant weight loss in sleep apnea patients, as well as cardiovascular benefits.

Left-leaning 0

No left-leaning outlet we follow has covered this.

Center 0

No center outlet we follow has covered this.

Right-leaning 2

Only this side used: lillysnext-generationcardiovascularinterruptions

• Fox News right

  Eli Lilly's retatrutide cut breathing interruptions and drove significant weight loss in sleep apnea patients, as well as cardiovascular benefits.
  
• Investor's Business Daily right

  Eli Lilly's next-generation weight-loss drug, retatrutide, trounced Novo's Ozempic in a head-to-head study, the company said Wednesday. The post Eli Lilly's Next-Gen Obesity Drug Trounces Ozempic In Head-To-Head Test appeared first on Investor's Business Daily.